TABLE 1.
Main characteristics of the studies included in this meta‐analysis and meta‐regression analysis.
| Author (Year) Ref. | Country /Continent | Age (median) | Regimen | Sample size (n) | Response rate (n) | mPFS (m) | OS (m) | NOS | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CR | PR | SD | PD | ORR (%) | DCR (%) | ||||||||
| Azizi (1979) 13 | US/NA | 52.3 | VAD | 6 | 3 | 1 | 2 | 0 | 66.6 | 100 | NR | NR | 6 |
| Hannigan(1983) 14 | US/NA | 54 | VDaCy | 14 | 3 | 1 | NR | NR | 28.5 | NR | NR | 19.3 | 7 |
| Omura (1983)( 15 )a | US/NA | 60 | A | 28 | 2 | 5 | 5 | 16 | 25 | 43 | 5.5 | 7.7 | 8 |
| Omura (1983) 15 b | US/NA | 61 | AD | 20 | 1 | 5 | 5 | 9 | 30 | 55 | 6 | 7.3 | 8 |
| Thigpen (1985) 16 | US/NA | 54 | Pz | 11 | 0 | 1 | 1 | 9 | 9 | 18 | NR | 2 | 7 |
| Thigpen (1986) 17 | US/NA | 54.8 | P | 19 | 1 | 0 | 7 | 11 | 5.3 | 42 | NR | NR | 6 |
| Hawkins (1990) 18 a | EN/EU | 47 | AI | 10 | 1 | 0 | 3 | 6 | 10 | 402 | NR | NR | 7 |
| Hawkins (1990) 18 b | EN/EU | 53 | I | 8 | 0 | 1 | 2 | 5 | 12.5 | 37.5 | NR | NR | 7 |
| Muss (1990) 19 | US/NA | 54 | MX | 12 | 0 | 0 | 2 | 10 | 0 | 16.6 | 1.4 | 4.1 | 7 |
| Thigpen (1991) 20 | US/NA | 53 | P | 33 | 0 | 1 | 18 | 14 | 3 | 57.5 | NR | NR | 6 |
| Sutton (1992) 21 | US/NA | 53 | I | 35 | 0 | 6 | 10 | 19 | 17 | 45.7 | NR | 6 | 7 |
| Currie (1996) 22 | US/NA | 55.6 | HUDE | 38 | 2 | 5 | 20 | 11 | 18.5 | 71 | NR | 15 | 7 |
| Thigpen (1996) 23 | US/NA | 54 | E | 28 | 0 | 0 | 13 | 15 | 0 | 46.4 | 2.1 | 9.2 | 7 |
| Sutton (1996) 24 | US/NA | 55 | AI | 33 | 1 | 9 | 17 | 6 | 30 | 81 | NR | 9.6 | 7 |
| Resnik (1996) 25 | US/NA | 49 | AEP | 7 | 1 | 1 | 5 | 0 | 28.6 | 100 | 25.5 | 43.1 | 7 |
| Rose (1998) 26 | US/NA | 54 | E | 29 | 0 | 2 | NR | NR | 6.9 | 6.9 | 2.1 | 7.6 | 7 |
| Sutton (1999) 27 | US/NA | 55 | Pt | 33 | 3 | 0 | 8 | 22 | 9 | 33.3 | 11 | NR | 7 |
| Miller (2000) 28 | US/NA | 53 | TOPO | 36 | 1 | 3 | 12 | 20 | 11.1 | 44.4 | NR | NR | 6 |
| Smith (2002) 29 | US/NA | 53 | TX | 23 | 0 | 1 | 11 | 11 | 4.4 | 52 | 2.2 | 7.2 | 7 |
| Pearl (2002) 30 | US/NA | 55 | AID | 5 | 1 | 1 | 1 | 2 | 40 | 60 | 13 | 43 | 7 |
| Edmonson (2002) 31 | US/NA | 52 | AMP | 35 | 3 | 5 | 14 | 13 | 22.8 | 62.8 | 4 | 6.3 | 7 |
| Hensley (2002) 32 | US/NA | 54 | GDt | 30 | 3 | 13 | 6 | 8 | 55.7 | 75.8 | 5.6 | 17.9 | 7 |
| Gallup (2003) 33 | US/NA | 53.5 | Pt | 48 | 2 | 2 | 11 | 33 | 8.3 | 31.2 | 1.5 | 12.1 | 7 |
| Look (2004) 76 | US/NA | 52.5 | G | 42 | 1 | 8 | 7 | 26 | 21.4 | 38 | NR | NR | 7 |
| Sutton (2005) 34 | US/NA | 52 | A | 30 | 1 | 4 | 10 | 15 | 16.6 | 50 | NR | NR | 6 |
| Long (2005) 35 | US/NA | 54.5 | AMDP | 16 | 1 | 4 | 10 | 1 | 31 | 93.7 | 5.9 | 14.2 | 7 |
| D'Adamo (2005) 36 | US/NA | 54 | AB | 7 | 0 | 2 | 4 | 1 | 28.6 | 85.7 | 8 | 16 | 7 |
| Boyar (2005) 37 | US/NA | 60 | TMZTha | 11 | 0 | 1 | 3 | 7 | 11 | 36 | 2 | 9.5 | 7 |
| Anderson (2005) 38 | US/NA | 52 | TMZ | 12 | 1 | 1 | 3 | 7 | 2/12 | 41.6 | NR | NR | 6 |
| Hensley (2008) 39 | US/NA | 50 | GDt | 45 | 3 | 10 | 24 | 8 | 28.8 | 82 | 6.7 | 14.7 | 7 |
| Hensley (2008) 40 | US/NA | 56.3 | GDt | 39 | 2 | 13 | 11 | 13 | 38.4 | 66.6 | 4.4 | 16.1 | 7 |
| Hensley (2009) 41 | US/NA | 56 | SU | 23 | 0 | 2 | 7 | 14 | 8.7 | 39 | 1.54 | 15.1 | 7 |
| Maki (2009) 42 | US/NA | 55 | SF | 37 | 0 | 1 | 18 | 18 | 2.7 | 51 | 3.2 | 22.4 | 7 |
| Sleijfer (2009) 43 | DU/EU | 56.6 | Pb | 34 | 0 | 1 | NR | NR | 2.9 | NR | 3 | 11.8 | 8 |
| Judson (2010) 44 | US/NA | 53 | Td | 62 | 0 | 11 | 20 | 31 | 17.7 | 50 | 2.5 | 12.1 | 7 |
| Sanfilippo (2011) 45 | IT/EU | 56 | Td | 66 | 0 | 11 | 23 | 32 | 16.6 | 51.5 | 3.3 | 14.4 | 7 |
| Monk (2012) 46 | US/NA | 60 | Td | 20 | 0 | 2 | 10 | 8 | 10 | 60 | 5.8 | 26.1 | 7 |
| Mackay (2012) 47 | US/NA | 58 | Aflibercept | 37 | 0 | 0 | 15 | 25 | 0 | 40.5 | 1.8 | 18.1 | 7 |
| Yoo (2012) 48 | US/NA | 54.8 | PtC | 8 | 0 | 1 | 1 | 6 | 12.5 | 25 | 2.23 | 12.4 | 6 |
| Pautier (2012)( 49 )a | FR/EU | 62 | GDt | 21 | 0 | 5 | 10 | 6 | 23.8 | 71.4 | 4.7 | 23 | 8 |
| Pautier (2012) 49 b | FR/EU | 64 | G | 21 | 1 | 3 | 9 | 8 | 19 | 61.9 | 5.5 | 20 | 8 |
| Takano (2014) 50 | JA/AS | 60 | GDt | 10 | 1 | 2 | 4 | 3 | 30 | 70 | 5.4 | 14 | 7 |
| Hadoux (2014) 51 | FR/EU | 51 | API | 33 | 4 | 12 | 8 | 9 | 48.5 | 72.7 | 9.8 | 27 | 7 |
| Yamagami (2014) 52 | JA/AS | 50 | API | 6 | 3 | 0 | 2 | 1 | 50 | 83 | 10.2 | NR | 7 |
| Duska (2014) 53 | US/NA | 56.5 | Ixabepilone | 21 | 0 | 0 | 4 | 17 | 0 | 19 | 1.4 | 7 | 7 |
| Pautier (2015) 54 | FR/EU | 58 | ATd | 47 | 0 | 28 | 13 | 6 | 59.5 | 87.2 | 8.3 | 27.5 | 7 |
| Seddon (2015) 55 | EN/EU | 53 | GDt | 24 | 0 | 8 | 7 | 9 | 33.3 | 62.5 | 7.1 | 17.9 | 7 |
| Benson (2016) 56 | US/NA | 55 | Pb | 44 | 0 | 5 | 25 | 14 | 11.3 | 68 | 3 | 17.5 | 8 |
| Hensley (2017) 57 a | US/NA | 55 | D | 88 | 1 | 6 | 26 | 55 | 8 | 37.5 | 1.5 | 12.9 | 8 |
| Hensley (2017) 57 b | US/NA | 54 | Td | 143 | 1 | 16 | 44 | 82 | 11.8 | 42.6 | 4 | 13.4 | 8 |
| Gelderblom (2017) 58 | DU/EU | 56 | Pb | 24 | 0 | 1 | 5 | 18 | 2.5 | 15 | 3 | 11.1 | 7 |
| Hyman (2017) 59 | US/NA | 61 | Ab | 21 | 0 | 0 | 8 | 13 | 0 | 38 | 1.7 | 14.5 | 7 |
| Kim (2018) 60 | KR/AS | 57 | Pb | 27 | 1 | 8 | 9 | 9 | 33 | 66.6 | 5.8 | 20 | 7 |
| Gadducci (2018) 61 a | IT/EU | 54 | GDt | 38 | 5 | 6 | 15 | 12 | 29 | 68.5 | 6.9 | 36.7 | 8 |
| Gadducci (2018) 61 b | IT/EU | 60 | Td | 115 | 8 | 19 | 43 | 45 | 23.5 | 61 | 4.1 | 20.6 | 8 |
| Sunar (2019) 62 | TU/AS | 53 | Pb | 28 | 0 | 4 | 17 | 7 | 14.3 | 75 | 5.2 | 11.4 | 8 |
Note: a and b denote the two armed studies.
Abbreviations: A, Adriamycin; AB, Adriamycin + Bevacizumab; Ab, Alisertib; ABl, Adriamycin + Bleomycin; AC, Adriamycin + Carboplatin; AD, Adriamycin + Dacarbazine; AEP, Adriamycin + Etoposide + cisplatin; AI, Adriamycin + Ifosfamide; AIDP, Adriamycin + Ifosfamide + Dacarbazine + Cisplatin; AIP, Adriamycin + Cisplatin + Ifosfamide; AMD, Adriamycin + Mitomycin + Dacarbazine: AMP, Adriamycin + Mitomycin + Cisplatin; AS, Asian; AT, Adriamycin + Trabectedin; B, Bevacizumab; Bl, Bleomycin; C, Carboplatin; CR, Complete response; Cy, Cyclophosphamide; D, Dacarbazine; Da, actinomycin‐D; DCR, Disease control rate; Dt, Docetaxel; DU, The Netherlands (Dutch); E, Etoposide; EN, England; EU, Europe; FR, France; G, Gemcitabine; GDt, Gemcitabine + Docetaxel; GDtB, Gemcitabine + Docetaxel + Bevacizumab; GE, Germany; HU, Hydroxyurea; HUDE, Hydroxyurea + Dacarbazine + Etoposide; I, Ifosfamide; IT, Italy; JA, Japan; KR, Korea; M, Mitomycin; m, months; N, Mitoxantrone; NA, North America; NOS, New Casttle Ottawa Scale; NR, Not reported; ORR, Overall response rate; OS, Overall survival; Pb, Pazopanib; PD, Progressive disease; PFS, Progression free survival; PR, Partial response; Pt, Paclitaxel; PtC, Paclitaxel + Carboplatin; Pz, Piperazinedione; SD, Stable disease; SF, Sorafenib; SU, Sunitinib; T, Trabectedin; Tha, Thalidomide; TMZ, Temozolomide; TOPO, Topotecan; TU, Turkey; TX, Trimetrexate; US, United States; V, Vincristine; VAD, Vincristine + Adriamycin + Dacarbazine; VDaCy, Vincristine + actinomycin‐D + Cyclophosphamide.